	US 11,813,311 B2
	Treatment and prevention of metabolic diseases
Stuart Alexander Cook, Singapore (SG); Sebastian Schaefer, Singapore (SG); Brijesh Kumar Singh, Singapore (SG); and Anissa Widjaja, Singapore (SG)
Assigned to Singapore Health Services PTE LTD., Singapore (SG); and National University of Singapore, Singapore (SG)
Filed by Singapore Health Services PTE LTD., Singapore (SG); and National University of Singapore, Singapore (SG)
Filed on May 1, 2020, as Appl. No. 16/865,259.
Claims priority of application No. 1906291 (GB), filed on May 3, 2019; application No. 2001013 (GB), filed on Jan. 24, 2020; application No. 2001896 (GB), filed on Feb. 12, 2020; and application No. 2002030 (GB), filed on Feb. 14, 2020.
Prior Publication US 2020/0384083 A1, Dec. 10, 2020 Prior Publication US 2021/0177940 A2, Jun. 17, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 38/20 (2006.01); A61P 3/00 (2006.01); C12N 15/113 (2010.01); C07K 16/24 (2006.01)

CPC A61K 38/2073 (2013.01) [A61P 3/00 (2018.01); C07K 16/244 (2013.01); C12N 15/1136 (2013.01); A61K 39/3955 (2013.01)]

8 Claims

1. A method of treating a metabolic disease, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject;

wherein the agent is selected from: (i) an anti-IL-11 antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof, or (ii) an anti-IL-11Rα antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof;

and wherein the metabolic disease is or comprises: obesity, being overweight, hyperglycaemia, pregnancy-associated hyperglycemia, insulin resistance, pre-diabetes, metabolic syndrome, hyperlipidaemia, hypertriglyceridemia, hypercholesterolemia, pancreatic insufficiency, pancreatitis, acute pancreatitis, chronic pancreatitis, lipotoxicity, or hyperglucagonemia.